U.S. markets open in 4 hours 37 minutes

LogicBio Therapeutics, Inc. (LOGC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.64-0.24 (-4.08%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Intermediate-term KST

Intermediate-term KST

Previous Close5.88
Open6.08
Bid0.00 x 800
Ask0.00 x 1200
Day's Range5.52 - 5.88
52 Week Range5.00 - 10.00
Volume121,903
Avg. Volume130,293
Market Cap180.627M
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-1.29
Earnings DateNov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • LogicBio Therapeutics to Present at 2021 Redburn Gene Therapy Summit
    PR Newswire

    LogicBio Therapeutics to Present at 2021 Redburn Gene Therapy Summit

    LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that chief executive officer Frederic Chereau will be participating on a panel at the 2021 Redburn Gene Therapy Summit. During the panel, entitled "Gene therapy: a changing regulatory landscape," Mr. Chereau will offer a brief overview of LogicBio and discuss the design of the SUNRISE clinical trial of LB-001 for the treatment of methylmalonic acidemia (MMA). The panel will take place at 9:15 a.m. EDT on Wednesday March 31st.

  • Health Check: How Prudently Does LogicBio Therapeutics (NASDAQ:LOGC) Use Debt?
    Simply Wall St.

    Health Check: How Prudently Does LogicBio Therapeutics (NASDAQ:LOGC) Use Debt?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • LogicBio Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update
    PR Newswire

    LogicBio Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update

    LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a clinical- stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today reported financial results for the year ended December 31, 2020 and provided a business update.